994P - Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (int...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Head and Neck Cancers
Surgical oncology
Therapy
Radiation oncology
Presenter Markus Hecht
Citation Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376
Authors M. Hecht1, D. Hahn2, D. Beutner3, D. Reichert4, T. Göhler5, R. Wurm6, M. Welslau7, L. Renziehausen8, P. Balermpas9, T. Bergmann10, M. Aßmann11, C. Belka12, K. Orlowski13, M. Finzsch13, G. Illerhaus2, R. Fietkau14
  • 1Radiation Oncology, Universitätsklinik Erlangen, 91054 Erlangen - Erlangen/DE
  • 2Hämatologie, Onkologie Und Palliativmedizin, Klinikum Stuttgart - Katharinenhospital Klinik f. Onkologie, Stuttgart/DE
  • 3Department Of Otorhinolaryngology, Head And Neck Surgery And Center For Integrated Oncology Köln Bonn, University Hospital Cologne, Köln/DE
  • 4Onkologie, Onkologie Westerstede Aurich Rhauderfehn, Westerstede/DE
  • 5Onkologie, Onkozentrum Dresden/Freiberg, Dresden/DE
  • 6Radiation Oncology, Klinikum Frankfurt (Oder), Frankfurt an der Oder/DE
  • 7Hämato-onkologische Schwerpunktpraxis, Klinikum Aschaffenburg, Aschaffenburg/DE
  • 8Onkologie, Praxis Drs. Renziehausen, Chemnitz/DE
  • 9Radiation Oncology, Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main/DE
  • 10Ii. Medizinische Klinik, SRH Waldklinikum Gera, Gera/DE
  • 11Praxis Dr. Aßmann, Elblandklinik, Riesa/DE
  • 12Radiation Oncology, Klinikum der Universität München, München/DE
  • 13Medical Affairs Oncology, Merck Serono GmbH, Darmstadt/DE
  • 14Radiation Oncology, Universitätsklinik Erlangen, Erlangen/DE

Abstract

Background

Cetuximab in combination with platinum-based chemotherapy followed by cetuximab monotherapy until progression significantly prolonged overall survival (OS) in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck (SCCHN) (EXTREME trial)1. SOCCER is a prospective, non-interventional study to evaluate symptom control in patients with recurrent and/or metastatic SCCHN treated with Cetuximab in combination with platinum-based chemotherapy or radiotherapy.

Methods

219 patients with recurrent and/or metastatic SCCHN were enrolled. Full information on the concomitant therapy were available for 196 patients. Response rates for the different Cetuximab containing therapy regimes as well as reasons for treatment discontinuations were evaluated.

Results

82 and 76 patients received Cisplatin or Carboplatin + Cetuximab, respectively, and 38 patients were treated with RT + Cetuximab for recurrent disease. Compared to the EXTREME trial, this study included more patients with metastatic disease (62% vs 47%) and more patients with an ECOG score of ≥2 (23% vs 12%). Median treatment duration of Cetuximab was 4.8 weeks in combination with radiotherapy and 11 weeks in combination with chemotherapy. Main reasons for Cetuximab treatment discontinuation was tumor progression (44%), death (14%) and patients wish (12%). Treatment was discontinued due to toxicities in 7% of the patients. Response data were available in 103 patients. The overall response rate (ORR) and the disease conrol rate (DCR) were 50 / 70% in the radiotherapy group, 43 / 76% in the Cisplatin group and 31 / 71% in the Carboplatin group, respectively.The median OS of 8.8 months and the median progression free survival of 5.0 months (both preliminary results) are comparabe to the results in the phase III EXTREME Trial.

Conclusions

The interim analysis of the SOCCER trial (non-selected patient cohort) is in agreement with the published efficacy and safety data of Cetuximab in combination with platinum-based chemotherapy in 1st line treatment of recurrent and/or metastatic SCCHN1. 1 Vermorken JB et al., N Engl J Med 2008; 359: 1116-11127.

Clinical trial identification

EMR062202-542

Legal entity responsible for the study

Merck Serono, Universitätsklinikum Erlangen

Funding

Merck Serono

Disclosure

M. Hecht: Research Funding: Novartis Honoraria for lecture: Merck Serono Travel expenses: TEVA, Merck Serono. K. Orlowski, M. Finzsch: employee Merck Serono GmbH. R. Fietkau: Advisor: Merck Serono, Novartis, Pierre Fabre Honoraria: Merck Serono, BrainLab, Fresenius, Novartis, Roche, Pierre Fabre. All other authors have declared no conflicts of interest.